Paradigm Biocapital Advisors LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$5.03B2026 Q3
Positions30
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.77.6%
What Changed This Quarter?
Top Holdings
RVMD
Revolution Medicines
25.4%
GMAB
Genmab A/S
10.0%
EWTX
Edgewise Therapeutics
8.7%
SYRE
Spyre Therapeutics
7.9%
INSM
Insmed
6.1%
MBX
MBX Biosciences
4.4%
ORKA
Oruka Therapeutics
4.1%
BLTE
Belite Bio
3.9%
New / Increased
8 new · 13 increased
BBIONEW
Bridgebio Pharma
3.1%
OBXNEW
Obsidian Therapeutics
1.1%
GPCRNEW
Structure Therapeutics
0.8%
MANENEW
Veradermics
0.7%
ORICNEW
Oric Pharmaceuticals
0.4%
INSM
Insmed
6.1%
+103.3%
MBX
MBX Biosciences
4.4%
+50.4%
SYRE
Spyre Therapeutics
7.9%
+16.1%
Reduced / Exited
6 reduced · 6 sold out
TARS
Tarsus Pharmaceuticals
3.6%
-17.1%
RVMD
Revolution Medicines
25.4%
-2.2%
ERAS
Erasca
2.3%
-16.2%
VOR
Vor Biopharma
0.3%
-49.2%
BLTE
Belite Bio
3.9%
-7.4%
NUVLEUREXIT
Nuvalent
13.7%
Apogee Therap…EXIT
Apogee Therapeutics
3.9%
ALNYEXIT
Alnylam Pharmaceuticals
2.7%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.